

Prescribing Formulary

Request

Please can you provide formulary information for the following products?

Please provide as much of the information requested as you are able. If this information is available in your formulary document please provide a link to the information

Could we also request a copy of your schizophrenia treatment protocol/guidelines?

	Abilify Tablets (aripiprazole)	Risperdal Consta (risperidone)	Xeplion (paliperidone)	(ZypAdhera) (olanzapine depot)
Approximate date of when the product was reviewed				
What evidence was used to help make the decision?				
What were the reasons for accepting/rejecting the product?				
Formulary positioning – 1st line Y/N				
Formulary positioning – 2nd line Y/N				
Formulary positioning – named patient Y/N				
Formulary positioning – specific patient types? If yes, which?				
Rationale for positioning				

Our Response

We follow NICE guidance for the pharmacological management of schizophrenia; please find attached our flowchart based on NICE Clinical Guideline 1.

	Abilify Tablets (aripiprazole)	Risperdal Consta (risperidone)	Xeplion (paliperidone)	(ZypAdhera)(olanzapine depot)
Approximate date of when the product was reviewed	April 2006	2005	Sept 2010	August 2010
What evidence was used to help make the decision?	Summary of product characteristics and formulary pack from company	Summary of product characteristics and formulary pack from company	Concise evaluated information to alert NHS Managers and Budget Holders to future drug technologies. Confidential for planning purposes only.	Formulary pack from Lilly
What were the reasons for accepting/rejecting the product?	Many other atypical antipsychotics available which are as effective and less costly. Not much to distinguish this as superior over others.	Only atypical long-acting injection available at the time.	Only atypical depot which does not have storage restrictions. Only atypical depot which can be given monthly.	Not many atypical antipsychotics available in injectable form and there is a need for them.
Formulary positioning – 1st line Y/N	N	N	N	N
Formulary positioning – 2nd line Y/N	Y	Y – if injectable formulation required	Y – if injectable formulation required	Y – if injectable form required
Formulary positioning – named patient Y/N	N	N	N	Y
Formulary positioning – specific patient types? If yes, which?	N	N	Y – patients showing response to risperidone oral medication	Y – patients responsive to olanzapine who require injectable formulation due to non-adherence to medication. Must consent to 3-hour post-administration monitoring in healthcare facility.
Rationale for positioning	Many other atypical antipsychotics available which are as effective and less costly. Not much to distinguish this as superior over others.	Only atypical long-acting injection available at the time.	Monthly depot, no storage restrictions – less wastage	Patients must consent to 3-hour post-administration monitoring in healthcare facility. Side effects can be very severe. Cannot be given in the community – has to be in healthcare facility.